{"id":46557,"date":"2025-10-10T17:25:29","date_gmt":"2025-10-10T11:55:29","guid":{"rendered":"https:\/\/financialtelegraph.in\/index.php\/2025\/10\/10\/transforming-cancer-care-earlysure-diagnostics-brings-precision-oncology-to-india\/"},"modified":"2025-10-10T17:25:29","modified_gmt":"2025-10-10T11:55:29","slug":"transforming-cancer-care-earlysure-diagnostics-brings-precision-oncology-to-india","status":"publish","type":"post","link":"https:\/\/financialtelegraph.in\/index.php\/2025\/10\/10\/transforming-cancer-care-earlysure-diagnostics-brings-precision-oncology-to-india\/","title":{"rendered":"Transforming Cancer Care: EarlySure Diagnostics Brings Precision Oncology to India"},"content":{"rendered":"
\n

\"Transforming<\/p>\n

New Delhi [India], October 10:<\/strong> A new era in Indian healthcare has begun with the inception of EarlySure Diagnostics Limited, a visionary venture poised to revolutionize advanced cancer diagnostics in India. As the exclusive partner of global liquid biopsy leader IMBDx Inc., EarlySure is set to redefine cancer management through minimally invasive, highly accurate solutions. Leading this transformation are two changemakers: Simrithi Bathija, the Miss India International titleholder turned Co-Founder & Chief Marketing Officer, and Pritam Lodh, the Co-Founder & Chief Technical Officer.<\/p>\n

For Simrithi Bathija, being crowned Miss India International marked the start of a mission where elegance meets earnest impact, turning the crown into a beacon for conversations around health, preventive care, and cancer awareness. Unlike many who gravitate towards fashion, Simrithi grounded her public journey in wellness and community empowerment. She champions the ethos that \u201ca fit mind and a fit body can change the way we live,\u201d emphasizing that responsibility must extend to one\u2019s own health.<\/p>\n

Now, as Co-Founder and Chief Marketing Officer, Simrithi aligns her focus on preventive lifestyle and early screening with the Prime Minister\u2019s\u00a0Healthy India (Swasth Bharat)mission. Her message, \u201cPreventive healthcare and awareness are not optional anymore\u2014they are the strongest shield we can give ourselves and our families,\u201d gains potent technical backing through EarlySure\u2019s solutions. With cancer burden in India projected to be roughly 12.8% higher in 2025 than in 2020, Simrithi\u2019s role is crucial in ensuring the dialogue around cancer stays visible, informed, and empowering. She embodies the idea that health is a collective movement and demonstrates that standing for something larger than self is the real hallmark of influence.<\/p>\n

Pritam Lodh: Pioneering Precision with Liquid Biopsy<\/p>\n

Pritam Lodh, Co-Founder & Chief Technical Officer, leads EarlySure\u2019s scientific initiatives.\u00a0With an MSc in Biotechnology, an MBA in International Business Management, a PGDM in Product Management, and an Advanced Diploma in Bioinformatics, Lodh is instrumental in bringing advanced precision oncology to India.\u00a0EarlySure\u2019s collaboration with IMBDx, a global leader in liquid biopsy and Comprehensive Genomic Profiling (CGP), enables them to overcome the limitations of traditional, invasive tissue biopsies.<\/p>\n

Pritam Lodh is dedicated to utilizing IMBDx\u2019s breakthrough technology, which analyzes cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) from a simple blood sample. This innovation, powered by Next-Generation Sequencing (NGS) and AI-driven bioinformatics, enables:<\/p>\n

\u25cf\u00a0Early cancer detection<\/p>\n

\u25cf\u00a0Real-time monitoring of tumor evolution<\/p>\n

\u25cf\u00a0Personalized treatment planning<\/p>\n

\u25cf\u00a0Reduced patient discomfort compared to surgical biopsy<\/p>\n

In a landscape where the liquid biopsy market is projected to surpass $20 billion globally by 2030, Lodh\u2019s vision is to make these advanced diagnostics accessible and affordable in India. \u201cThe future of oncology is non-invasive and predictive. We are not just bringing a test to India; we are delivering hope, accuracy, and a faster pathway to personalized treatment that bypasses the limitations and pain points of conventional methods,\u201d states Lodh. He highlights that up to 50% of all cancer cases are preventable, adding, \u201cBy adopting IMBDx\u2019s CancerDetect and CancerFind solutions, we are providing clinicians with actionable insights earlier, moving cancer care from late-stage reaction to true prevention and optimal therapeutic strategy.\u201d<\/p>\n

IMBDx introduces a comprehensive range of AlphaLiquid\u00ae and CancerDetect assays designed to transform cancer management through cutting-edge liquid and tissue biopsy technologies.<\/p>\n

AlphaLiquid\u00ae 100 \/ 1000: Comprehensive cfDNA-based profiling panels covering 192 to over 920 genes for treatment selection, monitoring, and biomarker discovery across solid tumors.<\/p>\n

AlphaLiquid\u00ae HRR: Specialized liquid biopsy assay targeting HRR gene alterations to identify patients eligible for PARP inhibitor therapies in prostate, ovarian, and breast cancers.<\/p>\n

AlphaLiquid\u00ae Breast: Focused cfDNA assay analyzing key breast cancer\u2013related genes such as ESR1, PIK3CA, and AKT1, supporting targeted therapy decisions.<\/p>\n

CancerDetect: A personalized MRD assay for early detection of cancer recurrence in post-operative patients.<\/p>\n

CancerFind\"\u2122\": A multi-cancer early detection (MCED) test utilizing whole-genome methylation sequencing for high-risk and healthy populations.<\/p>\n

With industry-leading turnaround times (7\u201314 days) and exceptional analytical sensitivity, IMBDx\u2019s genomic platforms empower oncologists and researchers to deliver truly personalized cancer care, improving outcomes through non-invasive precision diagnostics.<\/p>\n

Together, Simrithi Bathija and Pritam Lodh stand as visionary leaders, bridging the gap between national wellness aspirations and scientific accessibility. EarlySure Diagnostics is poised to be a force for change, proving that a crown shines brightest when it reflects responsibility and inspires industry-wide transformation.<\/p>\n

Disclaimer: <\/strong>This article is for general information purposes only and should not be construed as professional medical advice. Always consult your doctor before taking any step.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

New Delhi [India], October 10: A new era in Indian healthcare has begun with the inception of EarlySure Diagnostics Limited, a visionary venture poised to revolutionize advanced cancer diagnostics in … Read More<\/a><\/p>\n","protected":false},"author":1,"featured_media":46558,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[99],"tags":[680],"class_list":["post-46557","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-health","entry"],"_links":{"self":[{"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/posts\/46557","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/comments?post=46557"}],"version-history":[{"count":0,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/posts\/46557\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/media\/46558"}],"wp:attachment":[{"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/media?parent=46557"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/categories?post=46557"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/financialtelegraph.in\/index.php\/wp-json\/wp\/v2\/tags?post=46557"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}